Viking Therapeutics (VKTX) Enterprise Value: 2014-2025
Historic Enterprise Value for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $2.2 billion.
- Viking Therapeutics' Enterprise Value fell 63.17% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$321.7 million, marking a year-over-year decrease of 108.43%. This contributed to the annual value of $3.6 billion for FY2024, which is 138.86% up from last year.
- Viking Therapeutics' Enterprise Value amounted to $2.2 billion in Q3 2025, which was up 3.32% from $2.2 billion recorded in Q2 2025.
- Viking Therapeutics' Enterprise Value's 5-year high stood at $7.3 billion during Q1 2024, with a 5-year trough of -$116.0 million in Q1 2022.
- Its 3-year average for Enterprise Value is $3.0 billion, with a median of $2.2 billion in 2025.
- As far as peak fluctuations go, Viking Therapeutics' Enterprise Value plummeted by 151.04% in 2022, and later spiked by 1,593.54% in 2023.
- Quarterly analysis of 5 years shows Viking Therapeutics' Enterprise Value stood at $157.8 million in 2021, then spiked by 258.34% to $565.4 million in 2022, then surged by 165.21% to $1.5 billion in 2023, then spiked by 138.86% to $3.6 billion in 2024, then slumped by 63.17% to $2.2 billion in 2025.
- Its Enterprise Value was $2.2 billion in Q3 2025, compared to $2.2 billion in Q2 2025 and $1.9 billion in Q1 2025.